Journal of Clinical Oncology, Vol 8, 1777-1781, Copyright © 1990 by American Society of Clinical Oncology

ARTICLES

Treatment of testicular cancer: a new and improved model

LH Einhorn
Indiana University Medical Center, University Hospital, Indianapolis 46202.

Testicular cancer has become a model for a curable neoplasm. Prior to the advent of cisplatin combination chemotherapy, standard chemotherapy consisted of dactinomycin, alone or in combination with chlorambucil and methotrexate. Disseminated germ cell tumors were chemosensitive to these older regimens, with a 50% objective response rate and a 10% to 20% complete remission rate; however, the cure rate was only 5% to 10%. In 1974, we began our initial cisplatin plus vinblastine plus bleomycin (PVB) chemotherapy. Thirty-three of 47 patients with disseminated germ cell tumors treated from 1974 to 1976 achieved a complete remission (CR), and an additional five (11%) were rendered disease-free with post- PVB resection of teratoma or carcinoma. Twenty-seven (57%) of these patients are continuously disease-free with a minimal follow-up of 13 + years. Thus, cisplatin-based chemotherapy produced a one-log increase in the cure rate compared with dactinomycin. A subsequent phase III study performed from 1976 to 1978 demonstrated that the vinblastine dosage could be reduced 25% from 0.4 mg/kg to 0.3 mg/kg with a reduction in toxicity but without any decrement in therapeutic efficacy. A third-generation PVB study from 1978 to 1981 documented that optimal cure rates were achieved with 12 weeks of induction therapy with PVB and that long-term maintenance therapy with vinblastine was unnecessary. In 1978, we initiated salvage therapy with cisplatin plus etoposide (VP-16) in patients not cured with PVB, and 25% of these patients were subsequently cured with this regimen. This represented the first time an adult solid tumor had been cured with a second-line regimen. In 1983, we began studies with third-line therapy with cisplatin plus ifosfamide combination chemotherapy, and even in this refractory setting, approximately 20% of patients are curable. From 1981 to 1984, we compared cisplatin plus VP-16 plus bleomycin (PVP16B) with PVB as first-line chemotherapy. There was a significant reduction in neuromuscular toxicity favoring the VP-16 arm, and furthermore, 78% of these patients were continuously disease-free compared with 66% with PVB. Approximately 75% of patients with disseminated germ cell tumors will be cured with PVP16B, and an additional 10% are curable with salvage chemotherapy. This represents the highest cure rate in any adult malignancy.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. Kollmannsberger, S. Daneshmand, A. So, K. N. Chi, N. Murray, C. Moore, B. Hayes-Lattin, and C. Nichols Management of Disseminated Nonseminomatous Germ Cell Tumors With Risk-Based Chemotherapy Followed by Response-Guided Postchemotherapy Surgery J. Clin. Oncol., February 1, 2010; 28(4): 537 - 542. [Abstract] [Full Text] [PDF]

				K. Oechsle, M. Hartmann, W. Brenner, S. Venz, L. Weissbach, C. Franzius, S. Kliesch, S. Mueller, S. Krege, R. Heicappell, et al. [18F]Fluorodeoxyglucose Positron Emission Tomography in Nonseminomatous Germ Cell Tumors After Chemotherapy: The German Multicenter Positron Emission Tomography Study Group J. Clin. Oncol., December 20, 2008; 26(36): 5930 - 5935. [Abstract] [Full Text] [PDF]

				L. Marcon, B. F. Hales, and B. Robaire Reversibility of the Effects of Subchronic Exposure to the Cancer Chemotherapeutics Bleomycin, Etoposide, and Cisplatin on Spermatogenesis, Fertility, and Progeny Outcome in the Male Rat J Androl, July 1, 2008; 29(4): 408 - 417. [Abstract] [Full Text] [PDF]

				I. Shintaku, M. Satoh, E. Okajima, H. Fujimoto, T. Kamoto, O. Ogawa, K. Kawai, H. Akaza, T. Tsukamoto, S. Naito, et al. Survival of Metastatic Germ Cell Cancer Patients Assessed by International Germ Cell Consensus Classification in Japan Jpn. J. Clin. Oncol., April 1, 2008; 38(4): 281 - 287. [Abstract] [Full Text] [PDF]

				S. Culine, A. Kramar, C. Theodore, L. Geoffrois, C. Chevreau, P. Biron, B. B. Nguyen, J.-F. Heron, P. Kerbrat, A. Caty, et al. Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP J. Clin. Oncol., January 20, 2008; 26(3): 421 - 427. [Abstract] [Full Text] [PDF]

				R. de Wit Refining the Optimal Chemotherapy Regimen in Good Prognosis Germ Cell Cancer: Interpretation of the Current Body of Knowledge J. Clin. Oncol., October 1, 2007; 25(28): 4346 - 4349. [Full Text] [PDF]

				L. H. Einhorn, S. D. Williams, A. Chamness, M. J. Brames, S. M. Perkins, and R. Abonour High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors N. Engl. J. Med., July 26, 2007; 357(4): 340 - 348. [Abstract] [Full Text] [PDF]

				S Culine, P Kerbrat, A Kramar, C Theodore, C Chevreau, L Geoffrois, N. Bui, J Peny, A Caty, R Delva, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP) Ann. Onc., May 1, 2007; 18(5): 917 - 924. [Abstract] [Full Text] [PDF]

				L. H. Einhorn, M. J. Brames, B. Juliar, and S. D. Williams Phase II Study of Paclitaxel Plus Gemcitabine Salvage Chemotherapy for Germ Cell Tumors After Progression Following High-Dose Chemotherapy With Tandem Transplant J. Clin. Oncol., February 10, 2007; 25(5): 513 - 516. [Abstract] [Full Text] [PDF]

				T. D. Jones, M. Wang, M.-T. Sung, S. Zhang, T. M. Ulbright, J. N. Eble, S. D. Beck, R. S. Foster, J. J. Anagnostou Jr., C. Conner, et al. Clonal Origin of Metastatic Testicular Teratomas Clin. Cancer Res., September 15, 2006; 12(18): 5377 - 5383. [Abstract] [Full Text] [PDF]

				J. Aparicio, J. R. Germa, X. G. del Muro, P. Maroto, J. A. Arranz, A. Saenz, A. Barnadas, J. Dorca, J. Guma, D. Olmos, et al. Risk-Adapted Management for Patients With Clinical Stage I Seminoma: The Second Spanish Germ Cell Cancer Cooperative Group Study J. Clin. Oncol., December 1, 2005; 23(34): 8717 - 8723. [Abstract] [Full Text] [PDF]

				S. D. Fossa, J. Chen, S. J. Schonfeld, K. A. McGlynn, M. L. McMaster, M. H. Gail, and L. B. Travis Risk of Contralateral Testicular Cancer: A Population-based Study of 29 515 U.S. Men J Natl Cancer Inst, July 20, 2005; 97(14): 1056 - 1066. [Abstract] [Full Text] [PDF]

				P. Sawhney, C. J. Giammona, M. L. Meistrich, and J. H. Richburg Cisplatin-Induced Long-term Failure of Spermatogenesis in Adult C57/Bl/6J Mice J Androl, January 1, 2005; 26(1): 136 - 145. [Abstract] [Full Text] [PDF]

				D. Pectasides, M. Pectasides, D. Farmakis, G. Aravantinos, M. Nikolaou, M. Koumpou, A. Gaglia, V. Kostopoulou, N. Mylonakis, and D. Skarlos Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study Ann. Onc., March 1, 2004; 15(3): 493 - 497. [Abstract] [Full Text] [PDF]

				C. Kollmannsberger, J. Beyer, R. Liersch, P. Schoeffski, B. Metzner, J.T. Hartmann, O. Rick, K. Stengele, K. Hohloch, C. Spott, et al. Combination Chemotherapy With Gemcitabine Plus Oxaliplatin in Patients With Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group J. Clin. Oncol., January 1, 2004; 22(1): 108 - 114. [Abstract] [Full Text] [PDF]

				H.-J. Schmoll, C. Kollmannsberger, B. Metzner, J.T. Hartmann, N. Schleucher, P. Schoffski, J. Schleicher, O. Rick, J. Beyer, D. Hossfeld, et al. Long-Term Results of First-Line Sequential High-Dose Etoposide, Ifosfamide, and Cisplatin Chemotherapy Plus Autologous Stem Cell Support for Patients With Advanced Metastatic Germ Cell Cancer: An Extended Phase I/II Study of the German Testicular Cancer Study Group J. Clin. Oncol., November 15, 2003; 21(22): 4083 - 4091. [Abstract] [Full Text] [PDF]

				D. A. Vaena, R. Abonour, and L. H. Einhorn Long-Term Survival After High-Dose Salvage Chemotherapy for Germ Cell Malignancies With Adverse Prognostic Variables J. Clin. Oncol., November 15, 2003; 21(22): 4100 - 4104. [Abstract] [Full Text] [PDF]

				D. W. Brandli, T. M. Ulbright, R. S. Foster, O. W. Cummings, S. Zhang, C. J. Sweeney, J. N. Eble, and L. Cheng Stroma Adjacent to Metastatic Mature Teratoma after Chemotherapy for Testicular Germ Cell Tumors Is Derived from the Same Progenitor Cells as the Teratoma Cancer Res., September 15, 2003; 63(18): 6063 - 6068. [Abstract] [Full Text] [PDF]

				T. J. Sayers, A. D. Brooks, C. Y. Koh, W. Ma, N. Seki, A. Raziuddin, B. R. Blazar, X. Zhang, P. J. Elliott, and W. J. Murphy The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP Blood, July 1, 2003; 102(1): 303 - 310. [Abstract] [Full Text] [PDF]

				K. Kawai, J. Miyazaki, S. Tsukamoto, S. Hinotsu, K. Hattori, T. Shimazui, and H. Akaza Paclitaxel, Ifosfamide and Cisplatin Regimen is Feasible for Japanese Patients with Advanced Germ Cell Cancer Jpn. J. Clin. Oncol., March 1, 2003; 33(3): 127 - 131. [Abstract] [Full Text] [PDF]

				C. Kollmannsberger, O. Rick, H.-G. Derigs, N. Schleucher, P. Schoffski, J. Beyer, R. Schoch, H.G. Sayer, A. Gerl, M. Kuczyk, et al. Activity of Oxaliplatin in Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group J. Clin. Oncol., April 15, 2002; 20(8): 2031 - 2037. [Abstract] [Full Text] [PDF]

				R. de Wit, J. T. Roberts, P. M. Wilkinson, P. H.M. de Mulder, G. M. Mead, S. D. Fossa, P. Cook, L. de Prijck, S. Stenning, and L. Collette Equivalence of Three or Four Cycles of Bleomycin, Etoposide, and Cisplatin Chemotherapy and of a 3- or 5-Day Schedule in Good-Prognosis Germ Cell Cancer: A Randomized Study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council J. Clin. Oncol., March 15, 2001; 19(6): 1629 - 1640. [Abstract] [Full Text] [PDF]

				E. Fadel, B. Court, A. R. Chapelier, J. P. Droz, and P. Dartevelle One-stage approach for retroperitoneal and mediastinal metastatic testicular tumor resection Ann. Thorac. Surg., June 1, 2000; 69(6): 1717 - 1721. [Abstract] [Full Text] [PDF]

				E. W. Steyerberg, H. J. Keizer, D. T. Sleijfer, S. D. Fosså, D. F. Bajorin, A. Gerl, R. de Wit, W. J. Kirkels, H. S. Koops, and J. D. F. Habbema Retroperitoneal Metastases in Testicular Cancer: Role of CT Measurements of Residual Masses in Decision Making for Resection after Chemotherapy Radiology, May 1, 2000; 215(2): 437 - 444. [Abstract] [Full Text]

				W. P. Peters, R. D. Dansey, J. L. Klein, and R. D. Baynes High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Transplantation in the Treatment of Breast Cancer Oncologist, February 1, 2000; 5(1): 1 - 13. [Abstract] [Full Text]

				C. Bokemeyer, C. Kollmannsberger, C. Meisner, A. Harstrick, J. Beyer, B. Metzner, J. T. Hartmann, H.-J. Schmoll, L. Einhorn, L. Kanz, et al. First-Line High-Dose Chemotherapy Compared With Standard-Dose PEB/VIP Chemotherapy in Patients With Advanced Germ Cell Tumors: A Multivariate and Matched-Pair Analysis J. Clin. Oncol., November 1, 1999; 17(11): 3450 - 3456. [Abstract] [Full Text] [PDF]

				L. H. Einhorn, M. J. Stender, and S. D. Williams Phase II Trial of Gemcitabine in Refractory Germ Cell Tumors J. Clin. Oncol., February 1, 1999; 17(2): 509 - 509. [Abstract] [Full Text] [PDF]

				C. Bokemeyer, A. Gerl, P. Schoffski, A. Harstrick, N. Niederle, J. Beyer, J. Casper, H.J. Schmoll, and L. Kanz Gemcitabine in Patients With Relapsed or Cisplatin-Refractory Testicular Cancer J. Clin. Oncol., February 1, 1999; 17(2): 512 - 512. [Abstract] [Full Text] [PDF]

				J. A. Gietema, D. Th. Sleijfer, P. H. B. Willemse, H. S. Koops, E. van Ittersum, W. M. M. Verschuren, D. Kromhout, W. J. Sluiter, N. H. Mulder, and E. G. E. de Vries Long-term Follow-up of Cardiovascular Risk Factors in Patients Given Chemotherapy for Disseminated Nonseminomatous Testicular Cancer Ann Intern Med, May 1, 1992; 116(9): 709 - 715. [Abstract] [PDF]